Expanded CVX-300 Claims Are Spectranetics CEO’s First Order Of Business
This article was originally published in The Gray Sheet
Executive Summary
Incoming Spectranetics President/CEO John Schulte is pledging to fulfill the company's strategic goal to expand indications for the CVX-300 excimer laser, starting with critical limb (lower leg) ischemia
You may also be interested in...
Spectranetics Refocuses On CLI Indication After PELA Submission Setback
Spectranetics is considering whether to continue to pursue a claudication indication for its CVX-300 excimer laser in light of disappointing peripheral excimer laser angioplasty (PELA) trial results
Spectranetics Refocuses On CLI Indication After PELA Submission Setback
Spectranetics is considering whether to continue to pursue a claudication indication for its CVX-300 excimer laser in light of disappointing peripheral excimer laser angioplasty (PELA) trial results
Spectranetics Management Scuffle Outcome To Be Decided By Shareholders
Former Spectranetics CEO Joseph Largey and Chief Financial Officer Paul Samek could be reinstated to their previous positions if an alternative set of directors is elected at an upcoming shareholder meeting